Countries: Kenya; Uganda; Zambia; Rwanda; South Africa
Partners: Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya; Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI), Entebbe, Uganda; Zambia-Emory Research Project (ZEHRP)-Lusaka, Zambia; Projet San Francisco (PSF-Kigali)-Kigali, Rwanda; Desmond Tutu HIV Foundation (DTHF)-Masiphumele, Cape Town, South Africa; Medunsa, SA.
To conduct long-term follow-up and assess the long-term health status of volunteers who have been enrolled previously in an IAVI-sponsored trial of an investigational HIV vaccine candidate.
To evaluate the frequency of HIV infection in volunteers who participated in HIV vaccine clinical trials.
To evaluate the persistence of vaccine-induced antibodies in volunteers who tested HIV positive at the end of the IAVI-sponsored vaccine trial.
To characterize immunological, virological, and immunogenetic responses in volunteers participating in IAVI-sponsored clinical trials.